摘要
恶性肿瘤一直是当今世界最难攻克的顽疾之一,肿瘤靶向治疗以其高效低毒等特点为病人带来了新的希望,目前的靶向药物主要是单克隆抗体和小分子酪氨酸激酶抑制剂。微小RNA（micro RNA,mi RNA）是一类小的、进化保守的非编码RNA,负性调节编码基因以及非编码转录因子的表达,是各种细胞主要调控者,在肿瘤的发生、进展以及转移中发挥了重要的作用。研究显示,多种肿瘤均存在大量发挥癌基因或抑癌基因作用的mi RNA的表达失调,而这些表达异常的mi RNA已成为人们研制肿瘤靶向治疗的又一新工具。因此本研究就近年来mi RNA在肿瘤靶向治疗中的相关研究做一简要综述,以期为肿瘤的靶向治疗提供新的视角。
Malignant tumor is one of the most challenges in the world,target therapy of cancer with its characters of high-efficiency and low-toxicity brought new hopes to patients.There are two kinds of target drugs：monoclonal antibody and small molecular protein tyrosine kinases inhibitors.Micro RNAs（mi RNAs） are an evolutionarily cons-erved class of small,regulatory non-coding RNAs that negatively regulate protein coding gene and other non-coding transcripts expression.Mi RNAs have been established as master regulators of cellular processes,and they play a vital role in tumor initiation,progress ion and metastasis.Research shows that a lot of mi RNAs who play oncogenic and tumor suppressive roles were deregulated in several cancers.Based on these,mi RNAs may become the novel therapeutic tools in cancer management.In this review,we have focused on the roles of mi RNAs in the therapeutic strategies and anticipated to bring a new facet in the target therapy of cancer.
作者
赵洪焕
孔艺璇
章广玲
李玉凤
韩素桂
Zhao Honghuan;Kong Yixuan;Zhang Guangling;Li Yufeng;Han Sugui(Department of Pathogen Biology and Immunology, College of Basic Medical Sciences, North China University of Science and Technology, Tang- shan, 063000;Tangshan People＇s Hospital Affiliated to North China University of Science and Technology, Tangshan, 063000;Hebei Key Labora- tory for Chronic Diseases, Tangshan Key Laboratory for Preclinical and Basic Research on Chronic Diseases, School of Basic Medical Sciences, North China University of Science and Technology, Tangshan, 063000)
出处
《基因组学与应用生物学》
CAS
CSCD
北大核心
2018年第5期2272-2275,共4页
Genomics and Applied Biology
基金
国家自然科学基金资助课题(81201281)
河北省自然科学基金项目资助课题(C2012401037)
华北理工大学青年基金项目(z201607)共同资助
